Get the Stockscreener App
9.995
0.05%
0.005
Drugs Made In America Acquisition Corp stock is traded at $9.995, with a volume of 1,108.
It is up +0.05% in the last 24 hours and up +0.00% over the past month.
Drugs Made In America Acquisition Corp is a blank check company.
See More
Previous Close:
$9.99
Open:
$10.01
24h Volume:
1,108
Relative Volume:
0.02
Market Cap:
$304.57M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.05%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.00
$10.01
1-Week Range:
$9.98
$10.04
52-Week Range:
$9.96
$10.04
Drugs Made In America Acquisition Corp Stock (DMAA) Company Profile
Name
Drugs Made In America Acquisition Corp
Sector
Industry
Phone
-
Address
-
Compare DMAA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMAA
Drugs Made In America Acquisition Corp
|
10.00 | 304.57M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
7.695 | 2.25B | 3.13B | 50.80M | 555.00M | 0.1772 |
|
AACT
Ares Acquisition Corporation Ii
|
11.17 | 696.88M | 0 | 16.92M | -1.35M | 0.29 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.62 | 458.10M | 0 | 1.30M | 0 | 0.0301 |
|
AAM
Aa Mission Acquisition Corp
|
10.22 | 449.41M | 0 | 0 | 0 | 0.00 |
|
EQV
Eqv Ventures Acquisition Corp
|
10.04 | 447.53M | 0 | 0 | 0 | 0.00 |
Drugs Made In America Acquisition Corp Stock (DMAA) Latest News
7 Best Weight Loss Drug Stocks to Buy in 2025 | Investing | U.S. News - U.S News & World Report Money
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
Brokerages Set TWFG, Inc. (NASDAQ:TWFG) Target Price at $31.86 - Defense World
Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion | Eli Lilly and Company - Investors | Eli Lilly and Company
Drugs Made in America Acquisition Corp. Announces Advisory Team - GlobeNewswire
Popular cannabis brand declares Chapter 11 bankruptcy - TheStreet
Drugs Made In America Acquisition Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing February 25, 2025 - The Manila Times
Drugs Made In America Acquisition Corp. Announces The Separate Trading Of Its Ordinary Shares And Rights, Commencing February 25, 2025 - Marketscreener.com
Drugs Made In America Acquisition Corp. Announces Closing of Full Exercise of IPO Over-Allotment Option - TradingView
Drugs Made In America Acquisition Announces Closing Of Full Exercise Of IPO Over-Allotment Option - Marketscreener.com
Drugs Made In America Acquisition Corp.’s $200 Million Initial Public Offering - Global Legal Chronicle
Bain throws down $3.3B to acquire Japan's Mitsubishi Tanabe Pharma - FiercePharma
United Parcel Service (UPS) | History, Services, & Facts - Britannica
Drugs Made In America Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering - The Manila Times
Drugs Made In America Acquisition Prices $200 Million IPO -January 28, 2025 at 04:53 am EST - Marketscreener.com
Drugs Made in America Acquisition Corp. (DMAAU) Prices $200M IPO - SPACInsider
New Pharma SPAC Launches With $200M War Chest: Inside The Latest Healthcare IPO - StockTitan
Drugmakers hiked prices for hundreds of drugs in early January - NPR
The top 10 biopharma M&A deals of 2024 - FiercePharma
2024 drug approvals: Small companies loom large with several key FDA nods - FiercePharma
Bright Green enters into restructuring security agreement with Lynn Stockwell - Yahoo Finance
Bright Green (BGXX) Announces Major Restructuring: Founder Returns as CEO, Plans API Manufacturing Focus - StockTitan
On an investment spree, Lilly will spend $3B to expand newly acquired injectables plant in Wisconsin - FiercePharma
7 Companies Owned by Pfizer - Investopedia
Top 10 Asthma Drug Companies | Provides Best MedicinesMarket.us Media - Market.us Media - United States Market News
FTC’s watchdog role in pharma mergers: Road bumps and the way forward - Norton Rose Fulbright
IPO Roundup: Drugs Made in America Acquisition, FBS Global and more (NYSEARCA:IPO) - Seeking Alpha
BeiGene launches PD-1 drug Tevimbra at 10% discount to Merck's Keytruda - FiercePharma
23andMe Is Sinking Fast. Can the Company Survive? - WIRED
Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA Approved Drugs, Nutraceuticals and Supplements - GlobeNewswire
FTC v Actavis and pricing practices spearhead rise in US pharmaceutical antitrust cases - Global Competition Review
We bought what’s needed to make millions of fentanyl pills–for $3,600 - Reuters.com
Cosette Pharmaceuticals Acquires Ambien® and Ambien CR® (Zolpidem Tartrate) Tabs from Sanofi US in the US Market - BioSpace
Semnur Pharmaceuticals to go public in $2bn SPAC deal - Pharmaceutical Technology
China-made injectable PD-L1 drug flunks pivotal trial, forcing US partner to seek strategic options - FiercePharma
Top 10 smartest deals in biopharma - Fierce Biotech
Artificial Intelligence in Genomics Market Size US$ 16,431.16 Million by 2033 - BioSpace
Novo Nordisk announces $6B investment in Ozempic, Wegovy amid shortages - ABC News
Chinese Company Under Congressional Scrutiny Makes Key U.S. Drugs - The New York Times
Initial Public Offering (IPO) News Live Feed - StockTitan
Eli Lilly and Company - Britannica
Pfizer Inc. - Britannica
Bright Green invests $250m to expand facility in New Mexico - Pharmaceutical Technology
The top 10 drugs losing US exclusivity in 2024 - FiercePharma
Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know - CNBC
Novartis, Ono Latest to Announce Billion-Dollar M&A Deals - BioSpace
US launches antitrust investigation into UnitedHealth, WSJ reports - Reuters.com
Senate Report Exposes Big Pharma's Profiteering at Americans’ Expense - TechTarget
Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma
Obamacare Created Big Medicine - The Lever
Bright Green Corporation announces the agreement to acquire - GlobeNewswire
Drugs Made In America Acquisition Corp Stock (DMAA) Financials Data
There is no financial data for Drugs Made In America Acquisition Corp (DMAA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.09%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):